- SEC Filing
Save time and jump to the most important pieces.
SC 13D/A - Molecular Templates, Inc. (0001183765) (Subject)
SC 13D/A - Molecular Templates, Inc. (0001183765) (Subject)
SC 13G - Molecular Templates, Inc. (0001183765) (Subject)
AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced the appointment of Dr. Maurizio Voi to the role of Chief Medical Officer. Dr. Voi possesses more than 35 years of wide-ranging drug development experience. Dr. Voi will begin his new role on October 2, 2023. Dr. Voi joins MTEM from Novartis, where he served as Vice President, Global Program Head, for the PD-1 antibody Tislelizumab since April 2021. He was previously Global Program Head, Melanoma, at Novartis, a pos
Industry Veteran Gabriela Gruia, M.D., appointed to Board of Directors Megan Filoon promoted to General Counsel AUSTIN, Texas, March 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM" or "the Company"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced the appointment of Gabriela Gruia, M.D., to its Board of Directors and the promotion of Megan Filoon to General Counsel. "Dr. Gruia brings a wealth of industry knowledge to our Board of Directors," said Barry Selick, Ph.D., Chairman of the Board of Molecular
NOVATO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 29, 2021. Dr. Sanders, an experienced veteran of the biopharma industry, will serve as an independent director. "Dr. Sanders' established experience in global clinical development and especially with new technologies will be instrumental as we further advance our ongoing clinical trials and continue to expand our rare disease pipeline of novel therapeut
Monotherapy activity of long duration in patients who have progressed on checkpoint therapy via a novel immuno-oncology mechanism of action with PD-L1 ETB (MT-6402) programEarly indication of monotherapy activity in CTLA-4 ETB (MT-8421) program through T-reg depletion; no drug-related adverse events > grade 2Novel mechanism of action targeting CD38+ immune cells of B-cell, T-cell, and monocytic lineage representing enhanced potency in I&I without the need for conditioning therapy AUSTIN, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company focused on the discovery and development o
Continued monotherapy activity in solid tumors with MT-6402 (PD-L1-targeting ETB) in checkpoint-experienced patients.Early pre-clinical and clinical data demonstrate the potential of MT-0169 (CD38-targeting ETB) in severe immune-mediated diseases. AUSTIN, Texas, June 03, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage company focused on the discovery and development of targeted biologic therapeutics with unique mechanisms of action (engineered toxin bodies or "ETBs") for cancer and immune-mediated disease, today provided an update on its clinical-stage programs. Eric Poma, PhD., Chief Executive and Chief Scientific O
AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies ("ETBs"), to create novel therapies with potent differentiated mechanisms of action, today reported financial results and business updates for the first quarter of 2024. Recent Company Highlights MTEM presented clinical data at the 2024 AACR Annual Meeting that demonstrated MT-6402's tolerable safety and promising efficacy profile in relapsed/refractory HNSCC patients. As monotherapy in 7 evaluable HNSCC patient
4 - Molecular Templates, Inc. (0001183765) (Issuer)
4 - Molecular Templates, Inc. (0001183765) (Issuer)
4 - Molecular Templates, Inc. (0001183765) (Issuer)
BofA Securities initiated coverage of Molecular Templates with a rating of Buy and set a new price target of $12.00
UBS initiated coverage of Molecular Templates with a rating of Neutral and set a new price target of $13.00
4 - Molecular Templates, Inc. (0001183765) (Issuer)
DEF 14A - Molecular Templates, Inc. (0001183765) (Filer)
PRE 14A - Molecular Templates, Inc. (0001183765) (Filer)
8-K - Molecular Templates, Inc. (0001183765) (Filer)
Continued monotherapy activity in solid tumors with MT-6402 (PD-L1-targeting ETB) in checkpoint-experienced patients. Early pre-clinical and clinical data demonstrate the potential of MT-0169 (CD38-targeting ETB) in severe immune-mediated diseases.
Molecular Templates (NASDAQ:MTEM) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.78) by 110.26 percent. The company reported quarterly sales of $11.09 million which beat the analyst consensus estimate of $5.90 million by 87.99 percent. This is a 69.73 percent decrease over sales of $36.63 million the same period last year.